Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 6/20 | 0.43 |
| ▸ | CES1 | P23141 | 6/20 | 0.43 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.40 |
| ▸ | FFAR3 | O14843 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | CTSD | P07339 | 1/20 | 0.36 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4551461 | 0.85 | HAO1 (0.62) | CES2CES1HAO1ALDH1A1TSHR | |
| SCHEMBL992042 | 0.82 | — | — | |
| SCHEMBL1179018 | 0.82 | FAAH (0.44) | CES2CES1HAO1HDAC3HDAC1 | |
| SCHEMBL8069772 | 0.80 | TDP1 (0.45) | HAO1FFAR3ALDH1A1TSHRTET2 | |
| SCHEMBL8804004 | 0.76 | ALDH1A1 (0.45) | HDAC3HDAC1HDAC2HDAC8ALDH1A1 | |
| SCHEMBL1701664 | 0.76 | CES2 (0.53) | CES2CES1HAO1HDAC3HDAC1 | |
| SCHEMBL247453 | 0.75 | HAO1 (0.68) | CES2CES1HAO1HDAC3HDAC1 | |
| SCHEMBL6222141 | 0.75 | CES1 (0.50) | CES2CES1HAO1HDAC3HDAC1 | |
| SCHEMBL647475 | 0.75 | TSHR (0.52) | CES2CES1HDAC3HDAC1HDAC2 | |
| SCHEMBL1230322 | 0.75 | CES2 (0.63) | CES2CES1HAO1HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105111084-A | Synthesis method of 4-substituted-3-methyl-2,4-dioxobutyrate | UNIV TAIZHOU | 2015-12-02 | — | — | CN | disclosed |
| WO-2008100886-A1 | PREPARATION AND USE OF DEUTERATED UDENAFIL ANALOGUES AS HIGHLY SELECTIVE PDE5 MODULATORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
| US-20080194529-A1 | HIGHLY SELECTIVE and LONG-ACTING PDE5 MODULATORS | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194529-A1 | HIGHLY SELECTIVE and LONG-ACTING PDE5 MODULATORS | PDE5A, PDE7A, PDE3A | CES2 344/4885CES1 144/4885HAO1 1719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.